Compare CAI & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAI | TGTX |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.5B |
| IPO Year | 2025 | 2008 |
| Metric | CAI | TGTX |
|---|---|---|
| Price | $23.05 | $64.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | $34.23 | ★ $77.50 |
| AVG Volume (30 Days) | ★ 3.8M | 1.9M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.79 | ★ 1746.67 |
| EPS | 0.05 | ★ 0.52 |
| Revenue | ★ $812,033,000.00 | $2,785,000.00 |
| Revenue This Year | $28.81 | $61.95 |
| Revenue Next Year | $19.11 | $35.55 |
| P/E Ratio | $477.70 | ★ $124.76 |
| Revenue Growth | ★ 96.97 | N/A |
| 52 Week Low | $14.19 | $26.76 |
| 52 Week High | $36.50 | $68.03 |
| Indicator | CAI | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.26 | 64.72 |
| Support Level | $21.99 | $51.70 |
| Resistance Level | $23.66 | N/A |
| Average True Range (ATR) | 2.05 | 3.49 |
| MACD | -1.17 | 0.65 |
| Stochastic Oscillator | 3.45 | 73.78 |
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.